ARTH Settles into New Price Range as Chart Trends Upwards
Members,
Today we focus on ARTH. Arch Therapeutics is our new featured company as of early July and it is now time to breakdown where things stand for the company, its shareholders, and our members. We know what you’re thinking! ARTH is a bust… no good…. A dead horse! But, let’s not jump to such a quick conclusion. Yes, to date ARTH has not performed exactly like our last winning picks, however, like many previous companies we have profiled,ARTH may be a company that performs stronger thru the medium and long term than in the short. Shareholders have experienced a reduced share price since our introduction to the company, however, it is encouraging to see how well and balanced ARTH has traded at its new price. Here are the facts: Since ARTH reached its low of 0.415 on July 18, the share price has steadily increased in the right direction. For 6 of the last 7 trading days, ARTHhas closed in the green trending towards even higher break-out points. It is very easy for us to point this out after the fact, we know! But, as any good investor will tell you, often times the trend is your friend, and in this case it appears ARTH is poised to continue its steady climb up the charts. One thing is for sure, this company has all the tools in place to be an absolute success for its shareholders.
Arch Therapeutics is progressing well since it began trading in mid-June. The company has experienced key corporate developments that are shaping the ground work for the months ahead. In the middle of July, ARTH sent its co-founding and inventing scientist, Dr. Rutledge Ellis-Behnke, to the Nanomaterials Technology Conference in Corfu, Greece to deliver a keynote lecture titled “Translating Nanomedicine.” This is key as Dr. Ellis-Behnke was instrumental in discovering the hemostatic and other barrier properties of self-assembling peptides that could make future surgery and interventional care faster and safer through the development and proposed commercialization of the Company's flagship product candidate known as AC5™. The product is based on a self-assembling peptide solution that creates a physical, mechanical barrier, which could be applied to bleeding organs or wounds to seal leaking blood and other fluids.
Just days later on July 23, Arch Therapeutics announced Dr. Behnke spoke at the Annual CLINAM Nanomedicine Summit in Basel, Switzerland. Executive Director of CLINAM, said the goal of the 2013 Summit was "to bring together the most skilled people in an effort to help to shape this scientific field and thereby push the boundaries of cutting-edge Nanomedicine and Targeted Medicine."
"Dr. Ellis-Behnke is at the forefront of emerging trends in nanomedicine and the advice he provides our Company continues to be of great importance. He is the lead inventor on the intellectual property exclusively licensed by Arch Therapeutics from the Massachusetts Institute of Technology and his work offers strategic insights that shape our future and the roadmap for our success."
- Arch Therapeutics CEO, Dr. Terrence Norchi
ARTH – Corporate News Releases
A company is only as successful as the people involved. For Arch Therapeutics, the Company has one of the best assembled management and advisory boards we have ever seen in a small-cap company. At this point, the hype surrounding ARTH as a newly listed public company has slowed, but the promise of success from the people behind ARTHlooks very likely. Now that the speaking tour is complete, expect the people behind Arch Therapeutics to be getting to work. ARTH is on the forefront of medical developments and views its participation at the “Forefront of Emerging Trends in Nanomedicine” as an important step to its ongoing strategy for success.
For our members and all current shareholders, we encourage you to keep a close watch onARTH in the coming days. We have yet to see a major announcement from ARTH regarding corporate events and now that the speaking engagements are complete, the company will likely be hard at work. We have yet to see how the market reacts to key corporate developments. One thing is for sure, ARTH is trading very strong at its new price level and this may be the beginning of a nice trend in the coming weeks.
About Arch Therapeutics, Inc.(ARTH):
Arch Therapeutics, Inc. (ARTH) is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch's goal is to develop and commercialize products based on its innovative technology platform that make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate known as AC5™ is being designed to elegantly achieve hemostasis in minimally invasive and open surgical procedures. Find out more at www.archtherapeutics.com.
Sincerely,
The Bedford Team
